Compass Pathways, a UK-based psychedelic company, and Journey Clinical, a psychotherapy platform, have entered a research collaboration. They aim to explore the deployment and healthcare provider training model for COMP360 psilocybin treatment, for treatment-resistant depression (TRD), which is currently under FDA review.

The partnership will see both parties share information on the COMP360 program's delivery model. If COMP360 is approved for TRD, they will also investigate patient experiences, reimbursement processes, and potential innovative care pathways. Additionally, they will look into therapist training and treatment settings. 

Analyst QuickTake: As Compass Pathways nears FDA approval for its psilocybin program, it is actively partnering with others to support its product development initiatives. In January 2024, it partnered with Hackensack Meridian Health to support research efforts using psilocybin in mental health treatments. Also, during the same month, it partnered with Greenbrook TMS to explore delivery models for the COMP360 program.